214 related articles for article (PubMed ID: 26365425)
1. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
[TBL] [Abstract][Full Text] [Related]
2. Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis.
Abdel-Rahman O; ElHalawani H; Ahmed H
J Glob Oncol; 2015 Dec; 1(2):73-82. PubMed ID: 28804776
[TBL] [Abstract][Full Text] [Related]
3. Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H; Ahmed H
Future Oncol; 2015; 11(24):3307-19. PubMed ID: 26561878
[TBL] [Abstract][Full Text] [Related]
4. Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials.
Yang Y; Liu YH; Sun X; Yu MW; Yang L; Cheng PY; Yang GW; Wang XM
Curr Med Res Opin; 2017 Sep; 33(9):1663-1675. PubMed ID: 28665153
[TBL] [Abstract][Full Text] [Related]
5. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H
Expert Opin Drug Saf; 2015 Oct; 14(10):1495-506. PubMed ID: 26313327
[TBL] [Abstract][Full Text] [Related]
6. Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1229-42. PubMed ID: 25119858
[TBL] [Abstract][Full Text] [Related]
7. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Apr; 15(4):465-75. PubMed ID: 25664933
[TBL] [Abstract][Full Text] [Related]
8. Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Curr Med Res Opin; 2015 May; 31(5):975-86. PubMed ID: 25708852
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
Dolladille C; Font J; Bejan-Angoulvant T; Zaman K; Sassier M; Ezine E; Stefan A; Plane AF; Legallois D; Milliez P; Parienti JJ; Alexandre J
Arch Cardiovasc Dis; 2020; 113(6-7):420-432. PubMed ID: 32418884
[TBL] [Abstract][Full Text] [Related]
10. S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Abdel-Rahman O; ElHalawani H; Essam-Eldin S
Expert Opin Drug Saf; 2016 Jan; 15(1):5-20. PubMed ID: 26513339
[TBL] [Abstract][Full Text] [Related]
11. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015; 15(7):847-58. PubMed ID: 25994247
[TBL] [Abstract][Full Text] [Related]
12. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Jun; 14(6):751-60. PubMed ID: 24666215
[TBL] [Abstract][Full Text] [Related]
13. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
[TBL] [Abstract][Full Text] [Related]
14. Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials.
Li J; Gu J
Eur J Clin Pharmacol; 2017 Oct; 73(10):1209-1217. PubMed ID: 28710508
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials.
Liu M; Yang X; Liu J; Zhao B; Cai W; Li Y; Hu D
Oncotarget; 2017 May; 8(19):32258-32269. PubMed ID: 28416755
[TBL] [Abstract][Full Text] [Related]
16. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1063-73. PubMed ID: 24927771
[TBL] [Abstract][Full Text] [Related]
17. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1529-36. PubMed ID: 25159115
[TBL] [Abstract][Full Text] [Related]
18. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
[TBL] [Abstract][Full Text] [Related]
19. Risk of Gastrointestinal Events During Lapatinib Therapy: A Meta-Analysis From 12,402 Patients With Cancer.
Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
Am J Ther; 2018; 25(4):e412-e422. PubMed ID: 26938760
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials.
Sun W; Li J; Zhang Z; Su X
J Clin Pharm Ther; 2021 Apr; 46(2):241-255. PubMed ID: 33135237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]